Dr. Anthony Krajcer, a rheumatologist at The Polyclinic, is currently conducting a phase 4 clinical study comparing the safety and effectiveness of secukinumab 300mg to 150mg in patients with active ankylosing spondylitis.
About Ankylosing Spondylitis
Ankylosing spondylitis, or AS, is a form of arthritis that primarily affects the spine, although other joints can become involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. In more advanced cases, this inflammation can lead to ankyloses, a new bone formation in the spine, causing sections of the spine to fuse in a fixed, immobile position. AS can also cause inflammation, pain, and stiffness in other areas of the body such as the shoulders, hips, ribs, heels, and small joints of the hands and feet.
Secukinumab is known as a biologic and works by blocking the activity of a specific protein in the immune system, interlukin-17A, which is believed to be involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis.
This study is open to individuals who are 18 years or older with moderate to severe ankylosing spondylitis despite previous or current NSAIDs/non-biologic DMARDs, and/or anti-TNFa therapy.
All study visits will take place at The Polyclinic Madison Center. During the first 16 weeks of the study, all patients will receive 150mg secukinumab. At week 16, patients who have responded to treatment will be randomly assigned to either 150mg or 300mg secukinumab. The second treatment period will continue until Week 52.
There is no cost to participate in the study. Study treatment and all tests and procedures associated with the study are provided at no cost to you. You will receive financial compensation for your time.
For additional information, contact email@example.com or call 206.320.6766.